J&J Medical Connect
LAZCLUZE®

(lazertinib)

J&J Medical Connect

Connect with us

  • Products

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

LAZCLUZE - Dosage and Administration - Crushing, Splitting, or Dispersion of Tablets

Last Updated: 11/16/2026

SUMMARY  

  • LAZCLUZE (lazertinib) is a kinase inhibitor indicated in combination with RYBREVANT (amivantamab-vmjw) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 19 deletions (Exon19del) or Exon 21 L858R substitution mutations, as detected by a United States Food and Drug Administration (FDA)-approved test.1
  • LAZCLUZE is not commercially available as a solution or suspension.
  • Swallow LAZCLUZE tablets whole. Do not crush, split, or chew tablets.1
  • LAZCLUZE 80 mg or 240 mg tablet(s) can be dispersed in non-carbonated water for patients who have difficulty swallowing.1
  • The company cannot support any practices, procedures, or dosage administration techniques that deviate from the approved product labeling.
  • Please refer to the DOSAGE AND ADMINISTRATION section of the full Prescribing Information for complete information.1

Alternate Method of PREPARATION AND ADMINISTRATION

LAZCLUZE Tablets Prepared as a Dispersion in Water1

  • Place the tablet(s) required for the prescribed dose of LAZCLUZE into a small drinking cup.
  • Add at least 2 teaspoons (10 mL) of non-carbonated water.
  • Swirl gently until the tablet(s) are dispersed into small pieces. It may take up to           2 minutes to disperse the tablet(s).
  • Administer immediately after preparation.
  • Add at least 1 teaspoon (5 mL) of non-carbonated water to the same cup, swirl gently to suspend any remaining particles, then administer immediately to ensure that the full dose is received.
  • Discard any unused dispersion if not administered within 1 hour of preparation.

PRODUCT LABELING

Literature Search

A literature search of MEDLINE®, Embase®, BIOSIS Previews®, and Derwent Drug File (and/or other resources, including internal/external databases) was conducted on 13 November 2026.

References

1 LAZCLUZE (lazertinib) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/LAZCLUZE-pi.pdf

Would you like to clear and leave your conversation? Message history will be lost.